Inicio › Cáncer de colon › Tennessee
Ensayos clínicos de Cáncer de colon en Tennessee
21 estudios sobre Cáncer de colon buscan participantes en Tennessee.
Ciudades en Tennessee
Texto oficial del estudio (inglés)
A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07127874Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Henry-Joyce Cancer Clinic, Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07222800Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06128551A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Tennessee Oncology, PLLC, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07629960A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT07213609A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Provision Center For Biomedical Research, Knoxville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT07284849A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
- Ballad Health Cancer Center - Kingsport, Kingsport
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT07058012Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
ReclutandoSe aceptan voluntarios sanos
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07283939Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
Reclutando
Edades de 45 a 70 · Todos los sexos · Actualizado el 2 sept 2026 · NCT05080673Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- The West Clinic - Wolf River, Germantown
- Covenant Health Cancer Centers, Knoxville
- y 5 más
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT05174169Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 ago 2026 · NCT05433142A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- Sarah Cannon, SCRI Oncology Partners, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jun 2026 · NCT04678648A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
- SCRI Oncology Partners, Nashville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 jun 2026 · NCT07011576A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Vanderbilt University Medical Center, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 jun 2026 · NCT06051695A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jun 2026 · NCT06835569Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Sarah Cannon Research Institute, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 jun 2026 · NCT06040541A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Baptist Memorial Hospital Baptist Cancer Center, Memphis
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 27 may 2026 · NCT03093116Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Tennessee Oncology, Chattanooga
- Sarah Cannon Research Institute, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 may 2026 · NCT05379985Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 may 2026 · NCT06239194Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 mar 2026 · NCT00899626SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.